Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YAZ in Hidradenitis Suppurativa
NCT00722800Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ethinyl estradiol + drospirenone in hidradenitis suppurativa (HS), sponsored by Massachusetts General Hospital. Started Oct 2008; status: terminated.
02
Drugs
ethinyl estradiol + drospirenone
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT00722800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722800.